全文获取类型
收费全文 | 232676篇 |
免费 | 13486篇 |
国内免费 | 6486篇 |
专业分类
耳鼻咽喉 | 2822篇 |
儿科学 | 8774篇 |
妇产科学 | 3185篇 |
基础医学 | 17122篇 |
口腔科学 | 4664篇 |
临床医学 | 28260篇 |
内科学 | 40720篇 |
皮肤病学 | 3097篇 |
神经病学 | 12223篇 |
特种医学 | 12299篇 |
外国民族医学 | 22篇 |
外科学 | 33735篇 |
综合类 | 20862篇 |
现状与发展 | 26篇 |
预防医学 | 19044篇 |
眼科学 | 4484篇 |
药学 | 24324篇 |
109篇 | |
中国医学 | 4814篇 |
肿瘤学 | 12062篇 |
出版年
2023年 | 2192篇 |
2022年 | 4054篇 |
2021年 | 9601篇 |
2020年 | 5881篇 |
2019年 | 11677篇 |
2018年 | 6254篇 |
2017年 | 5498篇 |
2016年 | 7450篇 |
2015年 | 10274篇 |
2014年 | 18729篇 |
2013年 | 16567篇 |
2012年 | 19715篇 |
2011年 | 16523篇 |
2010年 | 15098篇 |
2009年 | 14783篇 |
2008年 | 13346篇 |
2007年 | 13360篇 |
2006年 | 11163篇 |
2005年 | 7395篇 |
2004年 | 3783篇 |
2003年 | 3297篇 |
2002年 | 2657篇 |
2001年 | 2110篇 |
2000年 | 1907篇 |
1999年 | 1185篇 |
1998年 | 1590篇 |
1997年 | 1419篇 |
1996年 | 1204篇 |
1995年 | 1288篇 |
1994年 | 1216篇 |
1993年 | 957篇 |
1992年 | 1174篇 |
1991年 | 1038篇 |
1990年 | 1077篇 |
1989年 | 1062篇 |
1988年 | 980篇 |
1987年 | 852篇 |
1986年 | 695篇 |
1985年 | 1634篇 |
1984年 | 1766篇 |
1983年 | 1275篇 |
1982年 | 1353篇 |
1981年 | 1342篇 |
1980年 | 1158篇 |
1979年 | 994篇 |
1978年 | 765篇 |
1977年 | 764篇 |
1976年 | 666篇 |
1974年 | 456篇 |
1973年 | 435篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
《Journal of Cardiovascular Computed Tomography》2022,16(6):483-490
BackgroundInflammation surrounding the coronary arteries can be non-invasively assessed using pericoronary adipose tissue attenuation (PCAT). While PCAT holds promise for further risk stratification of patients with low coronary artery disease (CAD) prevalence, its value in higher risk populations remains unknown.MethodsCORE320 enrolled patients referred for invasive coronary angiography with known or suspected CAD. Coronary computed tomography angiography (CCTA) images were collected for 381 patients for whom clinical outcomes were assessed 5 years after enrollment. Using semi-automated image analysis software, PCAT was obtained and normalized for the right coronary (RCA), left anterior descending (LAD), and left circumflex arteries (LCx). The association between PCAT and major adverse cardiovascular events (MACE) during follow up was assessed using Cox regression models.ResultsThirty-seven patients were excluded due to technical failure. For the remaining 344 patients, median age was 62 (interquartile range, 55–68) with 59% having ≥1 coronary artery stenosis of ≥50% by quantitative coronary angiography. Mean attenuation values for PCAT in RCA, LAD, and LCx were ?74.9, ?74.2, and ?71.2, respectively. Hazard ratios and 95% confidence intervals (CI) for normalized PCAT in the RCA, LAD, and LCx for MACE were 0.96 (CI: 0.75–1.22, p ?= ?0.71), 1.31 (95% CI: 0.96–1.78, p ?= ?0.09), and 0.98 (95% CI: 0.78–1.22, p ?= ?0.84), respectively. For death, stroke, or myocardial infarction only, hazard ratios were 0.68 (0.44–1.07), 0.85 (0.56–1.29), and 0.57 (0.41–0.80), respectively.ConclusionsIn patients referred for invasive coronary angiography with suspected CAD, PCAT did not predict MACE during long term follow up. Further studies are needed to understand the relationship of PCAT with CAD risk. 相似文献
12.
13.
《Health & place》2022
Interventions that involve key aspects of community organizing, such as quantitative community assessments and organizational partnership support for the community, may promote residents' health. We evaluated the effectiveness of this form of intervention on mortality and its variability across individual-level household equivalized income tertiles, comparing 52,858 residents aged 65 and above in 12 intervention municipalities to 39,006 residents in nine control municipalities in Japan. During 1,166 days of follow-up, the adjusted hazard ratio for cumulative mortality among men in the intervention municipalities was 0.92 (95% confidence interval: 0.86, 0.99) compared to those in the control group, with similar results being observed across all income levels. Active utilization of data to evaluate communities and building intersectoral partnerships might lower older male residents’ mortality risk, regardless of their income status. 相似文献
14.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):445-450
PurposeTo evaluate the effectiveness and safety of fluoroscopy-guided percutaneous high ligation (FPHL) combined with fluoroscopy-guided foam sclerotherapy (FGFS) to treat varicose veins of the great saphenous veins (GSVs).Materials and MethodsThis was a retrospective study of 113 patients (mean age, 62.1 ± 10.8 years; 60 men) with varicose veins of the GSVs (133 limbs) that were treated with FPHL combined with FGFS between April 1 and October 31, 2019. Demographic and clinical data were collected from these patients before the FPHL procedure, after which FGFS was performed. The preterminal GSV was ligated percutaneously by a percutaneously-positioned polypropylene ligature under fluoroscopic guidance. The outcome of ligation was confirmed by venography. Then, foam sclerotherapy was performed under fluoroscopy. At 1-year follow-up, GSV occlusion was evaluated by ultrasound. The venous clinical severity scores (VCSSs) were compared between the preoperative and 1-year follow-up periods.ResultsThe technical success rate was 100% (133 limbs). Complete 12-month follow-up was available for 112 limbs (84.2%) and 103 of these limbs (92.0%) remained occluded during this period. The VCSS improved from 4.71 ± 2.15 to 0.74 ± 0.60 (V = 6328, P < .001). During follow-up, there were 16 limbs with thrombophlebitis and 38 limbs with saphenous junction pain; these events were alleviated within 2 weeks of the procedure. There was no deep venous thrombosis or other severe adverse events.ConclusionsFPHL combined with FGFS to treat varicose veins in the GSVs achieved an occlusion rate of 92% and improved the clinical symptoms within 1 year; this minimally-invasive procedure was safe and effective. 相似文献
15.
18.
19.
20.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献